--- title: "AMRN.US (AMRN.US) — 相关新闻" type: "Symbol" locale: "zh-CN" url: "https://longbridge.com/zh-CN/quote/AMRN.US/news.md" symbol: "AMRN.US" name: "AMRN.US" parent: "https://longbridge.com/zh-CN/quote/AMRN.US.md" datetime: "2026-03-14T10:00:38.784Z" locales: - [en](https://longbridge.com/en/quote/AMRN.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/AMRN.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/AMRN.US/news.md) --- > 支持的语言: [English](https://longbridge.com/en/quote/AMRN.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AMRN.US/news.md) # AMRN.US (AMRN.US) — 相关新闻 ### [Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks](https://longbridge.com/zh-CN/news/278201930.md) *2026-03-07T06:55:49.000Z* > Amarin Plc is facing significant challenges as it relies on a single drug, Vascepa, which has lost key patent protection ### [Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk](https://longbridge.com/zh-CN/news/277739630.md) *2026-03-04T06:01:02.000Z* > Amarin Corporation Plc (AMRN) faces new risks regarding its revenue prospects in Europe, which depend on Recordati's exe ### [Amarin | 10-K: FY2025 Revenue Misses Estimate at USD 213.65 M](https://longbridge.com/zh-CN/news/277528253.md) *2026-03-02T22:34:03.000Z* ### [](https://longbridge.com/zh-CN/news/276921545.md) *2026-02-25T17:24:56.000Z* > Amarin shares are trading lower after the company reported a Q4 sales miss. ### [Amarin Q4 revenue falls 21% on lower sales outside US, Europe](https://longbridge.com/zh-CN/news/276883840.md) *2026-02-25T12:08:07.000Z* ### [Amarin | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 49.22 M](https://longbridge.com/zh-CN/news/276883788.md) *2026-02-25T12:07:25.000Z* ### [Amarin Corp Earnings Report: Q4 Overview](https://longbridge.com/zh-CN/news/276883623.md) *2026-02-25T12:04:27.000Z* > Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings on February 25, 2026, beating estimates by 101.79% with an EPS of $0.